Company news
Clinuvel Pharmaceuticals Limited news in 2016
Clinuvel Pharmaceuticals Limited's news releases, calls and decks from 2016, newest first.
Update on North American vitiligo program for SCENESSE
February 10, 2016
TGA grants Orphan Drug Designation for SCENESSE
February 10, 2016
Swiss insurers agree to reimburse Clinuvel`s SCENESSE
February 10, 2016
SCENESSE released for European Distribution
February 10, 2016
SCENESSE Commercialisation Update
February 10, 2016
S&P DJ Indices Announces March Quarterly Review
February 10, 2016
Positive preliminary results in Singaporean vitiligo study
February 10, 2016
Phase II study starts in skin disorder Hailey-Hailey Disease
February 10, 2016
NEJM publishes Phase III SCENESSE studies
February 10, 2016
Media release - US Phase II results
February 10, 2016
Management Update
February 10, 2016
Management change and regulatory review update
February 10, 2016
Italian Medicines Agency to reimburse afamelanotide for EPP
February 10, 2016
Half Yearly Report and Accounts
February 10, 2016
First positive observations from Clinuvel`s vitiligo trial
February 10, 2016
FDA grants Clinuvel a Type C Meeting
February 10, 2016
FDA allows US clinical trials of afamelanotide in EPP
February 10, 2016
FDA allows Clinuvel`s innovative vitiligo trial
February 10, 2016
European Commission approves SCENESSE
February 10, 2016
Encouraging interim safety results in Phase II OTR study
February 10, 2016
Clinuvel unveils SCENESSE following European brand approval
February 10, 2016
Clinuvel to start a Phase II vitiligo study in Singapore
February 10, 2016
Clinuvel Strategic Update
February 10, 2016
Clinuvel receives an unsolicited bid for the Company
February 10, 2016
Clinuvel Newsletter - February 2012
February 10, 2016
Clinuvel, FDA agree in principle to Phase III study
February 10, 2016
Clinuvel announces innovative melanocortin
February 10, 2016
Clinical significance and benefit from SCENESSE in US Phase
February 10, 2016
Appendix 4C
February 10, 2016
Decks in 2016
- Shareholder Meeting (November 2016)
Shareholder meeting · 28 slides · Nov 28, 2016
- Investor Presentation (February 2016)
Investor deck · 25 slides · Feb 8, 2016